In a dramatic turn of events, all independent board members of DNA testing company 23andMe have resigned, leaving only CEO Anne Wojcicki. The resignations stem from significant disagreements over the direction of the company's planned private buyout. Wojcicki expressed her 'surprise and disappointment' in a memo, noting her commitment to taking the company private. This upheaval follows the board's dissatisfaction with Wojcicki's buyout proposal, which they deemed unsatisfactory. The fallout has led to a 7% drop in 23andMe's stock as the company grapples with the implications of this mass resignation and the lack of a clear strategic path forward.